My Revolution of PARTs

BENGALURU: A lab at the Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR) will soon set up a National Centre of Excellence on Carbon Capture and Utilisation (NCCCU). This first of its kind centre that is being established will be the one of the two such centres being supported by the Department of Science and Technology (DST). The other centre will come up at IIT-Bombay (IIT-B), which has announced “the establishment of a National Centre of Excellence in Carbon Capture and Utilisation (NCoE-CCU) with support from the DST.” Sources said that the national centre coming up at the JNCASR will To perform world class research, provide training and consultancy in the areas of carbon-di-oxide (CO2) capture and utilisation and translate this research excellence into solutions with global economic and social impact. “The vision of the centre is to be a centre of excellence and world leader in niche research areas of CO2 capture and utilisation through high socioeconomic impac...

NEW DELHI: Drug firm Zydus Cadila on Thursday said it has received final approval from the US health regulator to market Nelarabine injection, used to treat certain types of cancer, in the American market with 180-days of marketing exclusivity. The company has received approval from the US Food and Drug Administration (USFDA) for the Nelarabine injection 250 MG/50ML, a generic version of Arranon injection. Zydus Pharmaceuticals USA Inc, a unit of the company, has been granted a competitive generic therapy (CGT) designation for the product and therefore is eligible for 180 days of exclusivity, Zydus Cadila said in a statement. According to IQVIA, Nelarabine injection had annual sales of around USD 34.5 million in the US. The drug is manufactured at the Zydus group's injection manufacturing facility in Ahmedabad and will be launched commercially within the US market immediately. The medication is a chemotherapy drug and is used to treat certain types of leukaemia and lymphoma by ...